Agendia Touts ASCO Guideline's Endorsement Of MammaPrint Breast Cancer Test

Results of the MINDACT trial, which show that Agendia BV's MammaPrint 70-gene lab test can identify about half of the early-stage breast cancer patients who do not need chemotherapy, has led the American Society of Clinical Oncology to specifically recommend the test in its guidelines.

Dividing Breast Cancer Cell
Dividing breast cancer cells • Source: Shutterstock

Agendia BV hopes adoption and reimbursement for its MammaPrint 70-gene breast cancer risk-of-recurrence test will get a boost from new American Society of Clinical Oncology guidelines (ASCO) that specifically recommend MammaPrint.

A focused update to ASCO's practice guidelines on biomarkers to guide decisions on adjuvant systemic therapy for women with early stage invasive breast cancer, published in the Journal...

More from Clinical Trials

More from R&D